As researchers push for a type 1 diabetes cure, Sana Biotechnology has provided a nudge forward with new, if limited, ...

and evasion of immune detection of HIP-modified primary pancreatic islet cells transplanted intramuscularly with no immunosuppression,” said Steve Harr, Sana’s President and Chief Executive ...

TD Cowen has recently raised Sana Biotechnology Inc (SANA) stock to Buy rating, as announced on January 8, 2025, according to Finviz. Earlier, on November 5, 2024, JMP Securities had reduced the stock ...

Sana Biotechnology (SANA), a clinical-stage ... modified islet cells were able to evade immune system attacks. CEO Steve Harr stated, “As far as we are aware, this is the first study showing ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology ... In the press release, Steve Harr, Sana's President and Chief ...

NASDAQ:SANA opened at $4.30 on Wednesday. The stock has a market cap of $960.06 million, a P/E ratio of -3.07 and a beta of 1.45. The company has a fifty day moving average price of $2.40 and a ...

SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ ... The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer ...

Analyst Price Forecast Suggests 518.18% Upside As of December 23, 2024, the average one-year price target for Sana Biotechnology is $10.20/share. The forecasts range from a low of $8.08 to a high ...

Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in reaction to a Phase 1 readout for its UP421 cell therapy, which, according ...